产品展示
GSK1904529A
点击次数：169发布时间：2013/4/3 15:46:20
更新日期：2022/8/19 17:45:40
所 在 地：美洲
产品型号：
优质供应
详细内容
GSK1904529A
上海义森生物科技有限公司
技术数据:
分子量（MW）: 851.96 
化学式: C44H47F2N9O5S
溶解度: DMSO 170mg/mL Water <1mg/mL Ethanol <1mg/mL 纯度: >99% 稳定性: at -20℃ 2 years CAS号: 1089283-49-7
生物活性
GSK1904529A, which potently inhibits IGF-IR （IC50= 27 nmol/L） ａnd IR （IC50= 25 nmol/L） activities in vitro ａnd in vivo, is a promising candidate for therapeutic use in solid ａnd hematologic cancers. [1]
IC50s for GSK1904529A in tumor cell lines ranged from 35 nmol/L to >30 umol/L.The tumor histologic types showing the greatest sensitivity to this compound were Ewing’s sarcoma ａnd multiple myeloma, where IC50s in three of five Ewing’s sarcoma cell lines were <100 nmol/L ａnd IC50s in five of eight multiple myeloma cell lines were <200 nmol/L .[1]
Oral administration of GSK1904529A decreases the growth of human tumor xenografts in mice.[1]
技术数据:
分子量（MW）: 851.96 化学式: C44H47F2N9O5S
溶解度: DMSO 170mg/mL Water <1mg/mL Ethanol <1mg/mL 纯度: >99% 稳定性: at -20℃ 2 years CAS号: 1089283-49-7
生物活性
GSK1904529A, which potently inhibits IGF-IR （IC50= 27 nmol/L） ａnd IR （IC50= 25 nmol/L） activities in vitro ａnd in vivo, is a promising candidate for therapeutic use in solid ａnd hematologic cancers. [1]
IC50s for GSK1904529A in tumor cell lines ranged from 35 nmol/L to >30 umol/L.The tumor histologic types showing the greatest sensitivity to this compound were Ewing’s sarcoma ａnd multiple myeloma, where IC50s in three of five Ewing’s sarcoma cell lines were <100 nmol/L ａnd IC50s in five of eight multiple myeloma cell lines were <200 nmol/L .[1]
Oral administration of GSK1904529A decreases the growth of human tumor xenografts in mice.[1]
技术数据:
分子量（MW）: 851.96 化学式: C44H47F2N9O5S
溶解度: DMSO 170mg/mL Water <1mg/mL Ethanol <1mg/mL 纯度: >99% 稳定性: at -20℃ 2 years CAS号: 1089283-49-7
生物活性
GSK1904529A, which potently inhibits IGF-IR （IC50= 27 nmol/L） ａnd IR （IC50= 25 nmol/L） activities in vitro ａnd in vivo, is a promising candidate for therapeutic use in solid ａnd hematologic cancers. [1]
IC50s for GSK1904529A in tumor cell lines ranged from 35 nmol/L to >30 umol/L.The tumor histologic types showing the greatest sensitivity to this compound were Ewing’s sarcoma ａnd multiple myeloma, where IC50s in three of five Ewing’s sarcoma cell lines were <100 nmol/L ａnd IC50s in five of eight multiple myeloma cell lines were <200 nmol/L .[1]
Oral administration of GSK1904529A decreases the growth of human tumor xenografts in mice.[1]
技术数据:
| 分子量（MW）: | 851.96 | |
|---|---|---|
| 化学式: | C44H47F2N9O5S | |
| 溶解度: | DMSO 170mg/mL Water <1mg/mL Ethanol <1mg/mL | |
| 纯度: | >99% | |
| 稳定性: | at -20℃ 2 years | |
| CAS号: | 1089283-49-7 |
生物活性
GSK1904529A, which potently inhibits IGF-IR （IC50= 27 nmol/L） ａnd IR （IC50= 25 nmol/L） activities in vitro ａnd in vivo, is a promising candidate for therapeutic use in solid ａnd hematologic cancers. [1]
IC50s for GSK1904529A in tumor cell lines ranged from 35 nmol/L to >30 umol/L.The tumor histologic types showing the greatest sensitivity to this compound were Ewing’s sarcoma ａnd multiple myeloma, where IC50s in three of five Ewing’s sarcoma cell lines were <100 nmol/L ａnd IC50s in five of eight multiple myeloma cell lines were <200 nmol/L .[1]
Oral administration of GSK1904529A decreases the growth of human tumor xenografts in mice.[1]
